Citations

Clear

1727 citation(s) found for "So, Alan".

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance)
Yuan, Chen , Sato, Kaori , Hollis, Bruce W. , Zhang, Sui , Niedzwiecki, Donna , Ou, Fang‐Shu , Chang, I-Wen, O’Neil, Bert H. , Innocenti, Federico , Lenz, Heinz‐Josef , Blanke, Charles D. , Goldberg, Richard M. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Venook, Alan P , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Venook, Alan P. , Mayer, Robert J. , Yuan, Chen

Mayo Clinic

Clinical Cancer Research | September 23, 2019 | Volume: 25 | Issue: 24 | Pages: 7497-7505

10.1158/1078-0432.ccr-19-0877 | PMID 31548349 Get It

Abstract Purpose: Previous studies have suggested that higher circulating 25-hydroxyvitamin D [25(OH)D] levels are associated with decreased colorectal cancer risk and improved survival. However, the influence of vitamin D status on disease progression and patient survival remains largely unknown for patients with advanced or metastatic colorectal cancer. Experimental Design: We prospectively collected blood samples in 1,041 patients with previously untreated advanced or metastatic colorectal cancer participating in a randomized phase III clinical trial of first-line chemotherapy plus biologic therapy. We examined the association of baseline plasma 25(OH)D levels with overall survival (OS) and progression-free survival (PFS). Cox proportional hazards models were used to calculate hazard ratios (HRs) and confidence intervals (CIs), adjusted for prognostic factors and confounders. Results: At study entry, 63% of patients were vitamin D deficient (<20 ng/mL) and 31% were vitamin D insufficient (20–<30 ng/mL). Higher 25(OH)D levels were associated with an improvement in OS and PFS (Ptrend = 0.0009 and 0.03, respectively). Compared with patients in the bottom quintile of 25(OH)D (≤10.8 ng/mL), those in the top quintile (≥24.1 ng/mL) had a multivariable-adjusted HR of 0.66 (95% CI, 0.53–0.83) for OS and 0.81 (95% CI, 0.66–1.00) for PFS. The improved survival associated with higher 25(OH)D levels was consistent across patient subgroups of prognostic patient and tumor characteristics. Conclusions: In this large cohort of patients with advanced or metastatic colorectal cancer, higher plasma 25(OH)D levels were associated with improved OS and PFS. Clinical trials assessing the benefit of vitamin D supplementation in patients with colorectal cancer are warranted.
Parental Attitudes Towards Prenatal Genetic Testing For Sickle Cell Disease
Stevens, Evelyn , Patterson, Chavis A. , Tchume‐Johnson, Trudy, Antiel, Ryan M. , Flake, Alan W. , Smith‐Whitley, Kim , Barakat, Lamia P.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | September 20, 2019 | Volume: 41 | Issue: 8 | Pages: 579-585

10.1097/mph.0000000000001592 | PMID 31568178 Get It

Uptake of prenatal genetic testing (PGT) is low among those with sickle cell disease (SCD). This study evaluated the association of knowledge and attitudes towards prenatal genetic counseling (PGC), awareness of posttesting intervention options and omission bias with attitudes towards PGT. In addition, we explored changes among knowledge, attitudes, and awareness of options following exposure to an educational, clinical vignette among parents of children with SCD. Parents (n=44) completed a questionnaire and an educational, clinical vignette presenting a detailed account of a pregnant woman with sickle cell trait seeking PGT and PGC was read to each participant.tTests, Spearman correlations, multivariable regressions, and moderation/mediation analyses were used. More positive attitudes towards PGC (P=0.01), lesser tendency of omission bias (P<0.01) and private insurance (P=0.04) were significant correlates of more positive attitudes towards PGT. Omission bias mediated the relationship of attitudes towards PGC and attitudes towards PGT (95% confidence interval: 0.13, 3.03). Awareness of options (P=0.02), knowledge of PGC (P=0.01) and knowledge of PGT (P=0.01) significantly improved after exposure to the clinical vignette. Patients and families with SCD can benefit from education about the importance of prenatal diagnosis to improve attitudes, address omission bias and promote more informed decisions of PGT.
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
Crow, Lauren , Jambusaria‐Pahlajani, Anokhi , Chung, Christina Lee , Baran, David A. , Lowenstein, Stefan E. , Abdelmalek, Mark, Ahmed, Rehana L. , Anadkat, Milan J. , Arcasoy, Selim M. , Berg, Daniel , Bibee, Kristin , Billingsley, Elizabeth M. , Black, William H., Blalock, Travis W. , Bleicher, Melissa, Brennan, Daniel C. , Brodland, David G., Brown, Mariah , Carroll, Bryan T. , Carucci, John A. , Chang, Timothy W., Chaux, George, Cusack, Carrie Ann, Dilling, Daniel F. , Doyle, Alden , Emtiazjoo, Amir , Ferguson, Nkanyezi H., Fosko, Scott W. , Fox, Matthew C., Göral, Simin , Gray, Alice , Griffin, John R., Hall, Shelley , Hanlon, Allison , Hayes, Don , Hickey, Gavin , Holtz, Jonathan E., Hopkins, R. Samuel, Hu, Jenny, Huang, Conway C. , Kapnadak, Siddhartha G. , Kraus, Edward S., Leitenberger, Justin J. , Lim, Mary Ann , Longo, María Isabel , Malik, Shahid M. , Menter, Alan , Myers, Sarah A., Neuburg, Marcy, Nijhawan, Rajiv I. , Norman, Douglas J., Otley, Clark C. , Paek, So Yeon , Parulekar, Amit , Patel, Manisha J., Patton, Timothy , Pugliano‐Mauro, Melissa , Ranganna, Karthik, Redenius, Rachel, Samie, Faramarz H. , Shin, Thuzar M. , Singer, Jonathan P. , Singh, Pooja , Soon, Seaver L. , Squires, Ronald A., Stasko, Thomas, Stein, Jennifer , Taler, Sandra J. , Thomas, Christie P. , Tokman, Sofya , Tomic, Rade , Twigg, Amanda R. , Wigger, M., Zeitouni, Nathalie C., Crow, Lauren D , Leca, Nicolae , Mallea, Jorge M. , Tomic, Rade , Singer, Jonathan P , Baran, David A , Paek, So Yeon , Ferguson, Nkanyezi , Hachem, Ramsey R. , Jiang, Shang I. Brian , Lease, Erika D. , Lee, James , Patel, Vishal Anil , Ravichandran, Ashwin Kumar , Redenius, Rachel A., Roll, Garrett Richard , Soriano, Teresa T. , Terrault, Norah A. , Arron, Sarah T. , Thomas, Christie P

Mayo Clinic

Transplant International | September 10, 2019 | Volume: 32 | Issue: 12 | Pages: 1268-1276

10.1111/tri.13520 | PMID 31502728 Get It

Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Arain, Mustafa A., Chen, Yi‐Jen , Ciombor, Kristen K. , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hoffe, Sarah E. , Hunt, Steven R., Kamel, Ahmed, Kirilcuk, Natalie, Krishnamurthi, Smitha , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Miller, Eric D. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Pedersen, Katrina S. , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Willett, Christopher G. , Johnson-Chilla, Alyse, Gregory, Kristina M., Gurski, Lisa A., Hubbard, Joleen, Miller, Eric D. , Meyerhardt, Jeffrey A , Pedersen, Katrina , Venook, Alan P. , Cohen, Stacey A. , Hubbard, Joleen M. , Patel, Hitendra, Saltz, Leonard B. , Schneider, Charles John , Stoffel, Elena M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2019 | Volume: 17 | Issue: 9 | Pages: 1109-1133

10.6004/jnccn.2019.0043 | PMID 31487687 Get It

Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.
Pseudomonas Aeruginosa Associated with Severity of Non-Cystic Fibrosis Bronchiectasis Measured by the Modified Bronchiectasis Severity Score (BSI) and the FACED: The US Bronchiectasis and NTM Research Registry (BRR) Study
Aksamit, Timothy R. , Stone, Glenda , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Choate, Radmila , Mannino, David M. , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Salathe, Matthias A. , Schmid, Andreas Alexander

Mayo Clinic

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5716-A5716

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5716 Get It

Airway Clearance in Non-Cystic Fibrosis Bronchiectasis: Analysis from the United States Bronchiectasis Research Registry
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Griffith, David E. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Turino, Gerard M., Winthrop, Kevin , O'Donnell, Anne E , Basavaraj, Ashwin , Choate, Radmila , Addrizzo‐Harris, Doreen , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5700-A5700

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5700 Get It

Interventions for replacing missing teeth: partially absent dentition
Abt, Elliot , Worthington, Helen V , Carr, Alan B.

Mayo Clinic

Cochrane Database of Systematic Reviews | August 19, 2019 | Volume: 2019 | Issue: 7 | Pages: No page available

10.1002/14651858.cd003814.pub3 | PMID 31425605 Get It

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Guercio, Brendan J. , Zhang, Sui , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , O’Neil, Bert H. , Polite, Blasé N. , Höchster, Howard S. , Atkins, James N., Goldberg, Richard M. , Sato, Kaori , Ng, Kimmie , Blarigan, Erin Van, Blanke, Charles D. , O’Reilly, Eileen M. , Fuchs, Charles S. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Niedzwiecki, Donna , Ou, Fang‐Shu , Venook, Alan P. , Shaw, James Edward , Blarigan, Erin L. Van , Mayer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | August 13, 2019 | Volume: 37 | Issue: 29 | Pages: 2620-2631

10.1200/jco.19.01019 | PMID 31408415 Get It

PURPOSERegular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored.PATIENTS AND METHODSWe conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850 ), a National Cancer Institute–sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss.RESULTSThe final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend= .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend= .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend< .001).CONCLUSIONAmong patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.